VivoSim Labs regains Nasdaq compliance after cash infusion

Go back to VivoSim Labs regains Nasdaq compliance after cash infusion

VivoSim Provides Financial and Listing Compliance Update

August 6, 2026 8:05 AM EDT

SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the Company or VivoSim), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced that on August 4, 2026, we received notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1) which requires registrants to maintain a minimum stockholders equity of $2.5M.

Subsequent to the filing of its recent Annual Report on Form 10-K for the fiscal year ended March 31,... More